Toggle navigation
Home
Search
Services
Blog
Contact
About
Rational Design of Neuropeptide Y Therapeutics
Salon, John A.
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States
Search 7 grants from John Salon
Search grants from Synaptic Pharmaceutical Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Proteomic analysis of S aureus biofilm in vivo
Apicomplexan Drug Target Discovery
Immune evasion in a humanized mouse model of HHV-6 infection
Early Identification of Adverse Reactions to Herbs
In Search of the Universal Nucleic Acid Base
Recently added grants:
Affinity-Mediated Covalent Conjugation: A Method for Direct Modification of Specific Receptors on Cell Membranes
Structure and Function of Serum Amyloid A in Health and Disease
Modeling and analysis of the mechanochemical processes that govern clathrin-mediated endocytosis
Correction of endocrine disruptor-induced transgenerational epimutations by CRISPR-dCas9
Gap Junctional Patterning in the Arrhythmic Heart
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS031843-03
Application #
2269799
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (13))
Project Start
1994-09-01
Project End
1996-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Synaptic Pharmaceutical Corporation
Department
Type
DUNS #
City
Paramus
State
NJ
Country
United States
Zip Code
07652
Related projects
NIH 1995
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
NIH 1994
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
Comments
Be the first to comment on this grant